Literature DB >> 22633487

A perspective on mammalian caspases as positive and negative regulators of inflammation.

Seamus J Martin1, Conor M Henry, Sean P Cullen.   

Abstract

Members of the caspase family of cysteine proteases coordinate the morphological and biochemical events that typify apoptosis. However, neutralization of caspase activity in mammals fails to block death in response to most proapoptotic stimuli. This is because many cell death triggers provoke mitochondrial dysfunction upstream of caspase activation as a consequence of BAX/BAK channel opening. Although genetic or pharmacological inactivation of caspases fails to block cell death in most instances, it does convert the phenotype from apoptosis to necrosis. This has important implications for how the immune system responds to such cells, as necrotic cells provoke inflammation whereas apoptotic cells typically do not. Here, we propose an alternative perspective on apoptosis-associated caspase function by suggesting that these proteases are activated, not to kill, but to extinguish the proinflammatory properties of dying cells. This perspective unifies the mammalian caspase family as either positive or negative regulators of inflammation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22633487     DOI: 10.1016/j.molcel.2012.04.026

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  66 in total

1.  Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics.

Authors:  Kristopher A Sarosiek; Cameron Fraser; Nathiya Muthalagu; Patrick D Bhola; Weiting Chang; Samuel K McBrayer; Adam Cantlon; Sudeshna Fisch; Gail Golomb-Mello; Jeremy A Ryan; Jing Deng; Brian Jian; Chris Corbett; Marti Goldenberg; Joseph R Madsen; Ronglih Liao; Dominic Walsh; John Sedivy; Daniel J Murphy; Daniel Ruben Carrasco; Shenandoah Robinson; Javid Moslehi; Anthony Letai
Journal:  Cancer Cell       Date:  2016-12-22       Impact factor: 31.743

Review 2.  Cell death in chronic inflammation: breaking the cycle to treat rheumatic disease.

Authors:  Holly Anderton; Ian P Wicks; John Silke
Journal:  Nat Rev Rheumatol       Date:  2020-07-08       Impact factor: 20.543

Review 3.  T Cells and Regulated Cell Death: Kill or Be Killed.

Authors:  Johan Spetz; Adam G Presser; Kristopher A Sarosiek
Journal:  Int Rev Cell Mol Biol       Date:  2018-08-29       Impact factor: 6.813

4.  IR820-loaded PLGA nanoparticles for photothermal therapy of triple-negative breast cancer.

Authors:  Danielle M Valcourt; Megan N Dang; Emily S Day
Journal:  J Biomed Mater Res A       Date:  2019-04-09       Impact factor: 4.396

Review 5.  Die another way--non-apoptotic mechanisms of cell death.

Authors:  Stephen W G Tait; Gabriel Ichim; Douglas R Green
Journal:  J Cell Sci       Date:  2014-05-15       Impact factor: 5.285

Review 6.  Inflammation and programmed cell death in Alzheimer's disease: comparison of the central nervous system and peripheral blood.

Authors:  Beatrice Macchi; Francesca Marino-Merlo; Caterina Frezza; Salvatore Cuzzocrea; Antonio Mastino
Journal:  Mol Neurobiol       Date:  2014-01-21       Impact factor: 5.590

Review 7.  Dying cells actively regulate adaptive immune responses.

Authors:  Nader Yatim; Sean Cullen; Matthew L Albert
Journal:  Nat Rev Immunol       Date:  2017-03-13       Impact factor: 53.106

8.  ZFX regulates glioma cell proliferation and survival in vitro and in vivo.

Authors:  Zhichuan Zhu; Kui Li; Dafeng Xu; Yongjie Liu; Hailiang Tang; Qing Xie; Liqian Xie; Jiwei Liu; Hongtao Wang; Ye Gong; Zelan Hu; Jing Zheng
Journal:  J Neurooncol       Date:  2013-01-16       Impact factor: 4.130

9.  Inhibition of tissue transglutaminase promotes Aβ-induced apoptosis in SH-SY5Y cells.

Authors:  Ji Zhang; Yi-Rong Ding; Rui Wang
Journal:  Acta Pharmacol Sin       Date:  2016-09-26       Impact factor: 6.150

Review 10.  Immunogenic cell death and DAMPs in cancer therapy.

Authors:  Dmitri V Krysko; Abhishek D Garg; Agnieszka Kaczmarek; Olga Krysko; Patrizia Agostinis; Peter Vandenabeele
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.